{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:37:43Z","timestamp":1793230663875,"version":"4.5.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaut.2025.103497","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T15:38:41Z","timestamp":1762270721000},"page":"103497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate"],"prefix":"10.1016","volume":"157","author":[{"given":"Zhenguo","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cheng-Chung Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5571-8728","authenticated-orcid":false,"given":"Dongze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103497_bib1","article-title":"Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019","volume":"64","author":"Collaborators","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/d41573-025-00061-7","article-title":"Trends in the drug target landscape for autoimmune diseases","volume":"24","author":"Fauconnier","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2025.103497_bib6","article-title":"Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy","volume":"16","author":"Liang","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/pharmrev.123.001084","article-title":"Precision medicine in rheumatic diseases: unlocking the potential of antibody-drug conjugates","volume":"76","author":"Huang","year":"2024","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ard.2025.02.009","article-title":"Chasing the target: reports from the advances in targeted therapies meeting, 2024","volume":"84","author":"Winthrop","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib13","first-page":"655","article-title":"FDA grants first US approval for decades-old eye drug","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib14","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The journey of antibody-drug conjugates: lessons learned from 40 years of development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib16","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","article-title":"The evolving landscape of antibody-drug conjugates: in depth analysis of recent research progress","volume":"34","author":"Sasso","year":"2023","journal-title":"Bioconjug. Chem."},{"issue":"739","key":"10.1016\/j.jaut.2025.103497_bib17","doi-asserted-by":"crossref","first-page":"eadd8936","DOI":"10.1126\/scitranslmed.add8936","article-title":"An anti-TNF-glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases","volume":"16","author":"McPherson","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib18","first-page":"340","article-title":"Antibody drug conjugate combats inflammation","volume":"23","author":"Crunkhorn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071807","article-title":"An overview of the development and preclinical evaluation of antibody-drug conjugates for non-oncological applications","volume":"15","author":"Pal","year":"2023","journal-title":"Pharmaceutics"},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2025.103497_bib22","article-title":"Therapeutic potential of imvotamab, a CD20-TARGETED bispecific igm T cell engager, for the treatment OF refractory autoimmune disease patients","volume":"83","author":"Domingo-Gonzalez","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ard.2025.06.491","article-title":"CND106, a novel bcma-directed t-cell engager (TCE), has a differentiated safety profile and potential for development in autoantibody-driven autoimmune diseases","volume":"84","author":"Tan","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib24","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.ard.2025.06.867","article-title":"KT501, a CD19, bcma-directed T-cell engager (TCE), leads to deep B-cell depletion and minimal cytokine release IN VIVO","volume":"84","author":"Wang","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-Cell-Engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103497_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ard.2025.05.454","article-title":"Effects of T cell engagers treatment on B and T cells in autoimmune disease","volume":"84","author":"Bucci","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib28","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ard.2025.06.870","article-title":"Safety and efficacy of T cell engager therapy in patients with refractory autoimmune disease","volume":"84","author":"Bucci","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"15","key":"10.1016\/j.jaut.2025.103497_bib29","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMc2506740","article-title":"BCMA T-Cell engager therapy in patients with refractory autoimmune disease","volume":"393","author":"Bucci","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.jaut.2025.103497_bib30","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1056\/NEJMc2502297","article-title":"BCMA-targeted T-Cell engager for autoimmune hemolytic anemia after CD19 CAR T-Cell therapy","volume":"392","author":"Zhang","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc2407150","article-title":"Teclistamab-induced remission in refractory systemic lupus erythematosus","volume":"391","author":"Alexander","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2025.103497_bib32","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ard.2025.06.353","article-title":"CC312, a CD19-TARGETING, CO-stimulatory CD28 receptor-activating tri-specific T cell engager, for the treatment of autoimmune diseases","volume":"84","author":"Huang","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ard.2025.05.394","article-title":"CC312, a novel engineered CD19\/CD3\/CD28 tri-specific ANTIBODY,LEADS to rapid and deep B-cell depletion and has broad potential for development in autoimmune diseases","volume":"84","author":"Qi","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib34","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.ymthe.2025.06.029","article-title":"Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4+ myasthenia gravis","volume":"33","author":"Schreiber","year":"2025","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib35","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.ymthe.2025.06.042","article-title":"CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes","volume":"33","author":"Ruck","year":"2025","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jaut.2025.103497_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.3274","article-title":"Biteing multi-drug resistant rheumatoid arthritis with CD19-T cell engagers","volume":"83","author":"Bucci","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib38","first-page":"1533","article-title":"BiTE therapy for rheumatoid arthritis","volume":"30","author":"Humby","year":"2024"},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib39","first-page":"411","article-title":"Bispecific antibody takes a BiTE out of B cells in rheumatoid arthritis","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2025.103497_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jaut.2025.103497_bib41","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ard.2025.06.464","article-title":"Treatment of severe systemic sclerosis with blinatumomab, a bispecific ANTI-CD3\/CD19 T cell engager","volume":"84","author":"Gebhardt","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib42","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.ard.2025.06.472","article-title":"The use of the CD3\/CD19 T cell engager blinatumomab in severe systemic sclerosis: a case series","volume":"84","author":"Scherlinger","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ard.2025.06.307","article-title":"Effects of the ANTI-CD3\/CD19 T-cell engager blinatumomab in severe systemic sclerosis","volume":"84","author":"Szelinski","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ard.2025.01.043","article-title":"Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation","volume":"84","author":"Siegert","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib45","first-page":"4","article-title":"Induction of gc-free remission by the bispecific cd19xcd3 t cell engager blinatumomab in patients with severe, therapy-refractory anti-synthetase syndrome","volume":"84","author":"Duesing","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117576","article-title":"Advances and challenges in immunosuppressive antibody drug conjugates","volume":"291","author":"Yaseen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib47","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1021\/acs.bioconjchem.8b00312","article-title":"Development of Anti-CD74 antibody-drug conjugates to target glucocorticoids to immune cells","volume":"29","author":"Brandish","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jaut.2025.103497_bib48","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ard.2025.06.027","article-title":"POS0666 immune-targeted glucocorticoid ADC for the treatment of autoimmune and inflammatory diseases","volume":"84","author":"Rothstein","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2025.103497_bib49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.4049\/jimmunol.168.2.883","article-title":"Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate","volume":"168","author":"Everts","year":"2002","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib50","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0006-2952(03)00122-9","article-title":"Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate","volume":"65","author":"Asgeirsd\u00f3ttir","year":"2003","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib51","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/mt.2012.103","article-title":"Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone","volume":"20","author":"Graversen","year":"2012","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib52","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/CCM.0b013e31828a45ef","article-title":"Targeting dexamethasone to macrophages in a porcine endotoxemic model","volume":"41","author":"Granfeldt","year":"2013","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amsu.2015.09.001","article-title":"Anti-CD163-dexamethasone protects against apoptosis after ischemia\/reperfusion injuries in the rat liver","volume":"4","author":"M\u00f8ller","year":"2015","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.jaut.2025.103497_bib54","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2016.11.004","article-title":"Antibody-directed glucocorticoid targeting to CD163 in M2-type macrophages attenuates fructose-induced liver inflammatory changes","volume":"4","author":"Svendsen","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib55","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1021\/jacs.5b12547","article-title":"Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody-drug conjugates","volume":"138","author":"Kern","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"16","key":"10.1016\/j.jaut.2025.103497_bib56","doi-asserted-by":"crossref","first-page":"11958","DOI":"10.1021\/acs.jmedchem.1c00541","article-title":"Development of novel glucocorticoids for use in antibody-drug conjugates for the treatment of inflammatory diseases","volume":"64","author":"Han","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib57","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1021\/acs.jmedchem.1c02099","article-title":"Design and development of glucocorticoid receptor modulators as immunology antibody-drug conjugate payloads","volume":"65","author":"Hobson","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.jaut.2025.103497_bib58","doi-asserted-by":"crossref","first-page":"15893","DOI":"10.1021\/acs.jmedchem.2c01579","article-title":"Discovery of ABBV-3373, an Anti-TNF glucocorticoid receptor modulator immunology antibody drug conjugate","volume":"65","author":"Hobson","year":"2022","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.jaut.2025.103497_bib59","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1021\/acs.jmedchem.3c01174","article-title":"Discovery of ABBV-154, an anti-TNF glucocorticoid receptor modulator immunology antibody-drug conjugate (iADC)","volume":"66","author":"Hobson","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib60","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1172\/JCI127101","article-title":"A promising approach to targeting type 1 IFN in systemic lupus erythematosus","volume":"129","author":"Chaichian","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib61","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of Anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib63","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib64","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/rheumatology\/kead219","article-title":"An immunomodulatory antibody-drug conjugate targeting BDCA2 strongly suppresses plasmacytoid dendritic cell function and glucocorticoid responsive genes","volume":"63","author":"Li","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2025.103497_bib65","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-0716-3682-4","article-title":"DB-2304, an immunomodulatory antibody-drug conjugate (ADC) targeting BDCA2, displays strong in vivo efficacy in pharmacodynamic and psoriasis models","volume":"76","author":"Li","year":"2024","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib66","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.jaut.2025.103497_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172914","article-title":"A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders","volume":"8","author":"Zhang","year":"2023","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib68","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1021\/jacs.5b00620","article-title":"An immunosuppressive antibody-drug conjugate","volume":"137","author":"Wang","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jaut.2025.103497_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.jaut.2025.103497_bib70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clim.2017.01.005","article-title":"High-dose BAFF receptor specific mAb-siRNA conjugate generates Fas-expressing B cells in lymph nodes and high-affinity serum autoantibody in a myasthenia mouse model","volume":"176","author":"Ibtehaj","year":"2017","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaut.2025.103497_bib71","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/mt.2016.175","article-title":"Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate","volume":"24","author":"Yu","year":"2016","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib72","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/rheumatology\/keg174","article-title":"Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs","volume":"42","author":"Wijngaarden","year":"2003","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib73","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/ard.2004.028845","article-title":"Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate","volume":"64","author":"van Roon","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib74","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/1529-0131(199908)42:8<1609::AID-ANR7>3.0.CO;2-L","article-title":"Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis","volume":"42","author":"Nakashima-Matsushita","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.jaut.2025.103497_bib75","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/art.21228","article-title":"Effectiveness of anti-folate receptor beta antibody conjugated with truncated pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages","volume":"52","author":"Nagayoshi","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib76","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1002\/art.22082","article-title":"In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells","volume":"54","author":"Nagai","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib77","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.4049\/jimmunol.1403012","article-title":"A new approach for the treatment of arthritis in mice with a novel conjugate of an Anti-C5aR1 antibody and C5 small interfering RNA","volume":"194","author":"Mehta","year":"2015","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib78","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - Common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib79","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1021\/acs.bioconjchem.7b00008","article-title":"Tocilizumab-alendronate conjugate for treatment of rheumatoid arthritis","volume":"28","author":"Lee","year":"2017","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/10717544.2017.1422295","article-title":"Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo","volume":"25","author":"Xie","year":"2018","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11255-4","article-title":"Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease","volume":"7","author":"Yasunaga","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib82","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2249.1995.tb03851.x","article-title":"High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints","volume":"102","author":"Gerli","year":"1995","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib83","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.4049\/jimmunol.164.8.4399","article-title":"CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role","volume":"164","author":"Gerli","year":"2000","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2025.103497_bib84","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.imlet.2014.01.007","article-title":"In rheumatoid arthritis soluble CD30 ligand is present at high levels and induces apoptosis of CD30(+)T cells","volume":"161","author":"Tinazzi","year":"2014","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.jaut.2025.103497_bib85","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00011-021-01537-z","article-title":"CD30-targeted therapy induces apoptosis of inflammatory cytokine-stimulated synovial fibroblasts and ameliorates collagen antibody-induced arthritis in mice","volume":"71","author":"Matsuhashi","year":"2022","journal-title":"Inflamm. Res."},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112473","article-title":"Initiation of fibronectin fibrillogenesis is an enzyme-dependent process","volume":"42","author":"Melamed","year":"2023","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112335","article-title":"Anti-fibrotic, muscle-promoting antibody-drug conjugates for the improvement and treatment of DMD","volume":"28","author":"Odeh","year":"2025","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib88","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood.2021012366","article-title":"A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice","volume":"139","author":"Saha","year":"2022","journal-title":"Blood"},{"issue":"8017","key":"10.1016\/j.jaut.2025.103497_bib89","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-024-07456-3","article-title":"Selective haematological cancer eradication with preserved haematopoiesis","volume":"630","author":"Garaud\u00e9","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib90","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jaut.2025.103497_bib91","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/rheumatology\/keu374","article-title":"Remission of rheumatoid arthritis on brentuximab vedotin","volume":"53","author":"Vachhani","year":"2014","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib92","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00277-018-3279-8","article-title":"Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated hodgkin lymphoma","volume":"97","author":"Nakazato","year":"2018","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib93","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12185-020-02822-z","article-title":"Successful treatment of methotrexate-associated classical hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series","volume":"111","author":"Ichikawa","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"17","key":"10.1016\/j.jaut.2025.103497_bib94","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2169\/internalmedicine.4417-20","article-title":"Methotrexate-associated Hodgkin lymphoma in a patient with rheumatoid arthritis successfully treated with brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (BV+AVD)","volume":"59","author":"Sekiguchi","year":"2020","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.jaut.2025.103497_bib95","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/jmc3636","article-title":"Hepatic hodgkin lymphoma presenting as solitary hepatic mass following other iatrogenic immunodeficiency-associated lymphoproliferative disorder in a patient with rheumatoid arthritis","volume":"12","author":"Tanaka","year":"2021","journal-title":"J. Med. Cases"},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib96","doi-asserted-by":"crossref","first-page":"154","DOI":"10.14740\/jh1035","article-title":"Durable remission in hodgkin lymphoma treated with one cycle of bleomycin, vinblastine, dacarbazine and two doses of nivolumab and brentuximab vedotin","volume":"11","author":"Yohannan","year":"2022","journal-title":"J Hematol"},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib97","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/rheumatology\/keae235","article-title":"Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial","volume":"64","author":"Fern\u00e1ndez-Codina","year":"2025","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jaut.2025.103497_bib98","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/rheumatology\/keae460","article-title":"Brentuximab vedotin compared with historical controls for severe skin involvement in cutaneous systemic sclerosis","volume":"64","author":"Fern\u00e1ndez-Codina","year":"2025","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bcp.15888","article-title":"A first-in-human study of the novel immunology antibody-drug conjugate, ABBV-3373, in healthy participants","volume":"90","author":"D'Cunha","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib100","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103497_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/art.43266","article-title":"Efficacy and safety of ABBV-154 for the treatment of active rheumatoid arthritis: a phase 2b, randomized, placebo-controlled trial","author":"Buttgereit","year":"2025","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2025.103497_bib102","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","article-title":"Polymyalgia rheumatica","volume":"402","author":"Esp\u00edgol-Frigol\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib103","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.43129","article-title":"Efficacy, safety, pharmacokinetics, and immunogenicity of ABBV-154 in adults with glucocorticoid-dependent polymyalgia rheumatica: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"77","author":"Spiera","year":"2025","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib104","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2039432","article-title":"Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils","volume":"11","author":"Leclercq","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jaut.2025.103497_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib106","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3324\/haematol.2023.283003","article-title":"Protracted viral infections in patients with multiple myeloma receiving bispecific T-cell engager therapy targeting B-cell maturation antigen","volume":"108","author":"Palmen","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib107","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s43856-024-00540-9","article-title":"Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers","volume":"4","author":"Karthikeyan","year":"2024","journal-title":"Commun. Med."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03391-z","article-title":"Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma","volume":"15","author":"Shan","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.jaut.2025.103497_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011200","article-title":"Characteristics of second primary malignancies following bispecific antibodies therapy","volume":"13","author":"Liang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jaut.2025.103497_bib110","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib111","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annemergmed.2024.10.015","article-title":"Antibody-drug conjugates: the toxicities and adverse effects that emergency physicians must know","volume":"85","author":"Markides","year":"2025","journal-title":"Ann. Emerg. Med."},{"issue":"2","key":"10.1016\/j.jaut.2025.103497_bib112","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.34507","article-title":"Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"129","author":"Zhu","year":"2023","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jaut.2025.103497_bib113","doi-asserted-by":"crossref","first-page":"e1435","DOI":"10.1093\/oncolo\/oyae177","article-title":"Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies","volume":"29","author":"Dy","year":"2024","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib114","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2024.07.1463","article-title":"Antibody-drug conjugates: a review of cutaneous adverse effects","volume":"91","author":"Saberi","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103497_bib115","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic toxicities of antibody-drug conjugates","volume":"91","author":"Gronbeck","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib116","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib118","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2665-9913(24)00338-2","article-title":"Evolution and trajectory of B-cell targeted therapies in rheumatic diseases","volume":"7","author":"Carter","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib119","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1600-6143.2011.03554.x","article-title":"Targeting B cells and antibody in transplantation","volume":"11","author":"Clatworthy","year":"2011","journal-title":"Am. J. Transplant."},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib120","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.ard.2025.06.2130","article-title":"Development of bispecific antibodies that drive selective targeted local complement inhibition on rheumatoid arthritis-related antigens","volume":"84","author":"Wang","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2025.103497_bib121","article-title":"Systematic review of safety and efficacy of Second- and third-generation CD20-Targeting biologics in treating immune-mediated disorders","volume":"12","author":"Kaegi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103497_bib122","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.ard.2025.06.906","article-title":"ABS1055 GB261 (CND261), a novel CD20\/CD3 T-cell engager, has a differentiated safety profile and potential for development in autoimmune diseases","volume":"84","author":"Song","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib123","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/19420862.2015.1022694","article-title":"Fab-based bispecific antibody formats with robust biophysical properties and biological activity","volume":"7","author":"Wu","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.jaut.2025.103497_bib124","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib125","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2020.1871171","article-title":"One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics","volume":"13","author":"Chen","year":"2021","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.jaut.2025.103497_bib126","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1158\/1535-7163.MCT-24-0846","article-title":"Optimization of a novel 2 + 2 BCMA \u00d7 CD3 bispecific antibody for minimized cytokine release and potent efficacy","volume":"24","author":"Wu","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib127","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2373325","article-title":"Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy","volume":"16","author":"McCue","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.jaut.2025.103497_bib128","series-title":"AnTenGagerTM, a novel \u201c2+ 1\u201d T cell engager platform, enables conditional T cell activation with reduced risk of CRS","author":"Hou","year":"2024"},{"issue":"748","key":"10.1016\/j.jaut.2025.103497_bib129","doi-asserted-by":"crossref","first-page":"eadl2720","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-Encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41375-022-01805-9","volume":"37","author":"Yu","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jaut.2025.103497_bib131","author":"Biopharma"},{"issue":"3","key":"10.1016\/j.jaut.2025.103497_bib132","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Tapia-Galisteo","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jaut.2025.103497_bib133","author":"Therapeutics"},{"issue":"7","key":"10.1016\/j.jaut.2025.103497_bib134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood.2024023849","article-title":"ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies","volume":"144","author":"Chang","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib136","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","article-title":"Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned","volume":"16","author":"L\u00f3pez de S\u00e1","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib137","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.jaut.2025.103497_bib138","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.jaut.2025.103497_bib139","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jaut.2025.103497_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116995","article-title":"Dual-payload antibody-drug conjugates: taking a dual shot","volume":"281","author":"Tao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib141","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2373330","article-title":"The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras","volume":"16","author":"Kelley","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.jaut.2025.103497_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115608","article-title":"Maximizing therapeutic potential and safety: exploring multi\/dual-payload antibody conjugates as cancer theranostics","volume":"222","author":"Khosravifarsani","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.jaut.2025.103497_bib143","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:11:44Z","timestamp":1773288704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125001428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":143,"alternative-id":["S0896841125001428"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103497","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune mediated inflammatory disease: T cell engager versus antibody drug conjugate","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103497"}}